Many factors can impact human lens epithelium biological behavior. Secreted protein acidic and rich in cysteine (SPARC) is a newly discovered protein that can impact cell activity and may potentially affect human lens epithelial cells (HLECs). HLEC (SRA01/04) proliferation was detected by methyl thiazolyl tetrazolium (MTT) and the proliferation index was assessed by flow cytometry with SPARC at concentrations of 0, 0.2, 1 and 5 μg/ml. SPARC's effect on cell cycle regulatory genes CCND1 and P21 Waf1 was analyzed by PCR and SPARC's effect on cell adhesion was detected by an enzyme labeling assay. SPARC displayed an inhibitory effect on HLEC proliferation. The amount of inhibition was related to SPARC concentrations and cell culture times. The inhibition rates were 9.67, 48.11 and 68.12% at concentrations of 0.2, 1 and 5 μg/ml, respectively, after 72 h of cell culture. With a MTT method, SPARC showed counter-adhesion of HLECs and this counter-adhesion was related to the concentration of SPARC. SPARC decreased the number of S+G2/M cells and caused G0/G1 phase arrest. With a 5 μg/ml SPARC treatment, CCND1 mRNA levels were significantly decreased and P21 Waf1 mRNA levels were increased in comparison with the control group. SPARC inhibits HLEC proliferation and adhesion, which is related to the SPARC concentration and cell culture time. Therefore, SPARC seems to influence HLEC biological behavior.
INTRODUCTION
Posterior capsule opacification (PCO) is a common postoperative complication following cataract extraction. The pathogenesis of PCO following cataract surgery is residual lens epithelial cells (LECs) migrate from the equator of the capsular bag and undergo myofibroblastic or fibroblastic-like changes (so called fibrous pseudometaplasia), which is then followed by the attached and proliferating LECs secreting a massive extracelluar matrix. PCO is the formation of a fibrotic membrane behind the artificial intraocular lens implanted *Corresponding author. E-mail: jsongz@yahoo.cn. Fax: 024-62689311. after the operation, which results in posterior capsual opacification and fiberation. This condition occurs in more than 50% of cataract patients within 5 years of surgery. The fibrotic membrane leads to blur, glare and light reflections. When the membrane encroaches on the visual axis, it gradually reduces visual acuity to blindness. This condition is initiated by the persistence of lens cells in the lens capsule after the cataract has been removed. Therefore, to reduce changes due to LECs, it is important to improve the success of surgery. Currently, worldwide research for the prevention of PCO focuses on the development of new and safe drugs, which will provide an effective treatment clinically.
Secreted protein acidic and rich in cysteine (SPARC) (Brekken et al., 2001 ) is a micromolecule protein that many cells secrete. It was first discovered and described by Termine et al. as an uncollagen composition in bones of humans and cows (Termine et al., 1981) . In the last 20 years, according to different denominations, basic SPARC has also been called 43 K (according to the size of protein), BM-40 (according to the tissue source) and osteonectin (according to the biochemical character of high affinity to the bone matrix) (Sage et al., 1984; Mann et al., 1987) . SPARC belongs to the class of matricellular proteins that also includes thrombospondin-1 and -2, osteopontin, and tenascins-C and -X. The human SPARC gene is a single copy gene that locates to 5q31-33. The protein coded by SPARC cDNA in vertebrates has 298 to 304 amino acids and is a signal peptide containing 77 amino acids followed by a hiding part that contains 283 to 287 amino acid residues.
Engel et al. proposed that SPARC contains four domains (Engel et al., 1987) . Domain (amino acid residues 3-51) is coded by exon 3, rich in acidity and has 5 to 8 binding sites to Ca ++ . The double coiled spiral structure in this domain is sensitive to the physiological outflow of Ca ++ concentrations (Mayer et al., 1991) . Domain (amino acid residues 52-132) is coded by exon 5, is rich in cysteine and has high homology to folliststin. This domain has GHK sequence and two binding sites to Cu ++ , which participate in regulating cell proliferation Sage, 1991, 1993) . Domain (amino acid residues 133-227) is coded by exon 7 and is known as an extending series of an α spiral fragment, which contains enzyme cutting sites of endogenous proteases. It combines to Cys247 of a domain located in the N end of this domain by a disulfide link (Lankat-Buttgereit et al., 1988) . Domain (amino acid residues 228 to 285) contains an EF arm coded by exon 9 and has high affinity to Ca ++ . SPARC can modulate cell shape, adhesion and migration by disrupting cell-ECM interactions, in part through its binding to several resident proteins of the ECM, such as fibrillar collagens (types I, III and V), collagen type IV and vitronectin (Brekken et al., 2001) . In addition to its counter-adhesive function, SPARC could modulate angiogenesis, stimulates the production of matrix metalloproteinases (Shankavaram et al., 1997; Tremble et al., 1993) and ECM proteins and influences the activity of cytokines and growth factors such as platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) (Motamed et al., 2002; Kupprion et al., 1998) . Furthermore, SPARC has been described as an inhibitor of cell cycle progression from G1 to S phase (Motamed et al., 2002; Francki et al., 2003) .
In recent years, research on SPARC has mainly focused on tumor studies. SPARC has a role in resisting cell proliferation and adhesion. Many studies focused on its inhibitory effect on many types of tumor cells, malpighian cells, lining epithelium cells of kidney cysts and the retinal pigment epithelium. In our present work, we investigated the effect of SPARC on human lens epithelial cell (HLEC) proliferation and adhesion to Bai et al. 6439 develop the potential drugs for PCO.
MATERIALS AND METHODS

Materials
PARC(C-15) is an affinity purified goat polycloned antibody raised against a peptide that maps at the C-terminus of human SPARC (From Santa Cruz Biotechnology Inc.). HLECs (from a cell line of immortalized HLEC SRA01/04) were provided by the Cancer Institute of the Chinese Academy of Medical Sciences.
Cell culture
HLECs were seeded onto DMEM medium supplemented with 10% fetal calf serum and were cultured for 24 h at 37°C and 5% CO2. The medium was then removed and new medium was added every 2 to 3 days. An inverted microscope was used to observe the growing condition of the cells. Serial sub-cultivations of the cells were performed with 0.25% trypsin digestion when 70 to 80% cell confluence was observed.
Proliferation assay by methyl thiazolyl tetrazolium (MTT)
HLECs at an exponential growth phase were seeded onto a 96-well plate containing DMEM supplemented with 10% fetal calf serum and were cultured for 24 h. The medium was then removed and new medium was added with different concentrations of SPARC (0 μg/ml -control, 0.2, 1 and 5 μg/ml) and the explants were grown for 24, 48 or 72 h based on the primary study result. Each concentration treatment was performed in 6 wells. HLECs were dyed with trypan blue after culture and the number of living cells was 95% or more. MTT (5 g/L) was added to the medium 4 h before the end of culturing. 620 nm was selected as the reference absorbance wavelength for the enzyme labeling assay and the reading of light density was obtained at 540 nm. The experiment was repeated 2 times and the average reading was calculated.
Cell cycle and proliferation index (PI) assay
HLECs at an exponential growth phase were seeded onto a 96-well plate and cultured with different concentrations of SPARC (0, 0.2, 1 and 5 μg/ml) supplemented with 10% fetal calf serum at 37°C and 5 % CO2 for 72 h. The medium was then digested with 0.25 % trypsin, the cells were collected and washed with PBS, pre-cooling alcohol was added into the wells and the cells were incubated at -20°C for overnight. The samples were centrifuged at 15,000 r/min for 10 min and the cells were then washed by PBS and dyed. Flow cytometry was used to detect the cell cycle. The data were analyzed by using Multi-Cycle software. The PI was calculated with the following formula:
Cell cycle controlling gene (CCND1 and P21 Waf1 ) assay
HLECs at an exponential growth phase were seeded onto a 96-well plate and cultured with different concentrations of SPARC (0, 0.2, 1 and 5 μg/ml) supplemented with 10% fetal calf serum at 37°C and 5% CO2 for 72 h. The medium was then digested with 0.25% trypsin and the cells were collected. The cells were cleaved by adding 1 ml of Trizol and the RNA was extracted with phenol and 
Primer
Primer sequence PCNA P1 5-CTCAAGAAGGTGTTGGAGGCA-3 PCNA P2 5-GTCGCAGCGGTAGGTGTCG-3 CCND1
P1 5-CTGGATGCTGGAGGTCTG-3 CCND1
P2 5-GGATGGAGTTGTCGGTGTA-3 β-actin P1 5-TCCTCCTGAGCGCAAGTACTCT-3 β-actin P2 5-GCTCAGTAACAGTCCGCCTAGA-3 chloroform. A 20 μl reaction system of reverse transcription was applied, which contained 1 μl of RNA, 1 μl of RT buffer and 0.5 μl of oligo, 0.5 μl of AMV reverse transcriptase, 1 μl of dNTP mixture (10 mmol/L), 3.75 μl of RNase-free dH2O and 2 μl of MgCl2. Reaction parameters were 50°C for 30 min, 99°C for 5 min and 5°C for 5 min. A 40 μl of reaction system for PCR contained 10 μl of 5×PCR buffer, 28.75 μl of dH2O, 0.25 μl of TaKaRa Ex TaqHS, 0.5 μl of primer 1 and 0.5 μl of primer 2. The reaction condition was set as follows for the first 5 cycles: apomorphosis in advance at 95°C for 180 s, apomorphosis at 94°C for 30 s, anneal at 56°C for 30 s and extend at 72°C for 45 s, and the reaction conditions were subsequently extended up to 30 cycles. Last, the product of PCR was identified by agarose gel electrophoresis and was scanned by a gel imaging system. The changes in CCND1 and P21 Waf1 expression were calculated by their reinhoit Zahl. β-actin was used as an interior control and the sequences of primers used are presented in Table  1 .
Cell adhesion assay
After the HLECs were serially subcultured, suspensions of 1 × 10 8 HLECs were made with different concentrations of SPARC (0, 0.2, 1 and 5 μg/ml) supplemented with 10% fetal calf serum and incubated at 37°C and 5% CO2 for 30 min. Cell suspensions were then seeded onto a 96-well plate containing rat tail protein, 100 μl per well and 6 wells for each concentration, and were incubated at 37°C and 5% CO2 for 8 h. At the end of incubation, the supernatant of the suspensions was removed and the wells were washed with culture fluid twice to eliminate the unattached cells. 100 μl culture fluid containing 2% fetal calf serum and 10 μl MTT (5 μg/ml) were added into each well and the culture was continued for 3 h. The culture fluid was removed and 100 μl DMSO was added into each well. The samples were kept at 37°C for 10 min and then the OD values were read at 570 nm wavelength, according to the enzyme labeling assay protocol.
Statistical analysis
The data were analyzed by a t-test with Minitab software. P values of 0.05 or less were considered significant. Table 2 shows the effect of different concentrations of SPARC on the HLEC proliferation at different times. SPARC had an inhibitory effect on HLEC proliferation and the inhibition was related to SPARC c oncentrations and cell culture times. The inhibition was observed at 0.2 μg/ml but was not statistically significant (P > 0.05). There was a significant decrease of HLEC proliferation as the concentration of SPARC increased and as the cell culture time was prolonged. Table 3 shows the inhibition rate of SPARC to HLEC proliferation with 5 μg/ml SPARC and Table 4 presents the inhibition rate of SPARC with different concentrations at 72 h of culture. The inhibition rates were detected as 9.67, 48.11 and 68.12% with 0, 0.2, 1 and 5 μg/ml respectively, after 72 h cell culture (Table 4) .
RESULTS
Effect of SPARC on the HLEC proliferation
Effect of SPARC on the HLEC cell cycle
Cell cycles were detected by flow cytometry and the rates of cell cycle phases are shown in Table 5 . The number of HLECs at S and G 2 /M stages decreased gradually with an increase in SPARC concentration. HLEC growth stopped at the G 0 /G 1 stage and the proliferation index decreased gradually.
Effect of SPARC on CCND1 and P21
Waf1 gene expressions Figure 1 shows expression levels for cell cycle controlling genes CCND1 and P21 Waf1 with 5 μg/ml SPARC. Compared with the control group, the CCND1 mRNA levels significantly decreased and for P21 Waf1 increased (Tables 6 and Figure 1 ).
Effect of SPARC on HLEC adhesion
SPARC inhibits HLEC adhesion (Table 7) .
DISCUSSION
SPARC belongs to an extracellular matrix protein family whose function is to regulate the interaction of cells and the matrix. It has been demonstrated in vitro that the inhibition of cell proliferation and adhesion is the major function of SPARC. It regulates the expression of cell cycle genes and stops the cells at the G 1 stage. SPARC inhibits cell proliferation by regulating the activity of growth factors such as PDGF, fibroblast growth factor 2 (FGF-2) and VEGF (Brekken et al., 2000) . It has been demonstrated that a local solution for adhesion and recombination of actin fibers results in being adhesion free. Francki et al. confirmed , by protein sequencing, that SPARC produced the phenomenon of being adhesion free (Francki et al., 2003) .
To investigate the role of SPARC in HLEC proliferation and adhesion, we performed a series of studies in vitro, such as detecting cell proliferation by MTT, enzyme labeling assay and OD values and flow cytometry 
Concentration (μg/ml)
Inhibitory ratio (%) 0.2 9.67 ± 0.01 1 48.11 ± 0.01 5 68.12 ± 0.01 detecting cell cycles. The results showed that SPARC was inhibitory to HLEC proliferation and adhesion. The inhibition was related to SPARC concentration and cell culture times. It was also observed that SPARC, at 1 µg/ml or a higher concentration, increased the number of G 0 /G 1 stage cells and decreased the number of S stage cells, which indicates that SPARC inhibited cell proliferation by regulating the cell cycle. The cell cycle is the final pathway of cell proliferation. There are restriction points in the majority of cell cycle phases, with the point between the G 1 and S stage as most important. At this restriction point, cells integrate and transfer many intracellular and extra-cellular signals, and then decide whether they will enter the cleavage process, stay at a resting stage or proceed to apoptosis (Pardee, 1989) . The key elements of cell cycle regulation are cell cycle genes, which produce cyclin dependent kinase (CKD), cell cyclin and CKD inhibiting factor (CKDI) (Chan et al., 2001 ). CyclinD1, coded by CCND1, is an important cyclin that regulates the G 1 stage. It becomes a compound with the combination of CKD, regulates CKD kinase by phosphorylation and facilitates expression of some genes that encourage cells passing the restriction point between the G 1 and S stages and entering the independent cleavage process (Wang et al., 2004) . P21
Waf1 is a CKD inhibitor that can inhibit the activity of CKD or cyclinD1-CKD compound and make them dephosphorylate, which inhibits cell proliferation (Fotedar et al., 2004) . We observed in our experiments that SPARC acted on HLECs and significantly decreased the level of CCND1 mRNA and increased the level of P21 Waf1 mRNA when compared to the control group. This indicates that the regulation of SPARC on HLEC cell cycles was completed through inhibiting expression of CCND1 and encouraging expression of P21 Waf1 , which blocked cells from passing the restriction point between G 1 and S stages and inhibited cell proliferation. HLECs play an important role in cataract development and any factor leading to abnormality of HLEC structure and function will result in crystal opacitas. Postsurgical lens capsule opacitas is related to HLECs, so the biological behavior of HLECs is considered most important for cataract and postsurgical capsular opacity.
Our experiments demonstrated that, in vitro, exogenous SPARC inhibits HLEC proliferation and adhesion from a gene level, which we believe provides a new direction for research on cataract and posterior capsular opacity. Since SPARC is a micromolecule protein secreted by many cells in vivo and is safe, as are most other proliferation inhibitors, it may be a new candidate for the prevention of postsurgical capsular opacity in the near future. However, many further studies need to be done to explore the specific mechanisms of secretion, regulation and the contribution of SPARC in HLECs. 
